Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19
Shown To Cut Deaths By 8%
After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.
You may also be interested in...
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.